Answers are grounded in this paper and cite their sources.
The quest for new antibiotics, especially those with activity against Gram-negative bacteria, is urgent; however, very few new antibiotics have been marketed in the last 40 years, with this limited number falling into only four new structural classes. Several nucleoside natural product antibiotics target bacterial translocase MraY, involved in the lipid-linked cycle of peptidoglycan biosynthesis, and fungal chitin synthase. Biosynthetic studies on the nikkomycin, caprazamycin and pacidamycin/mureidomycin families are also reviewed.
No takes yet. Share an insight, caveat, or question.
Winn et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: